Published in Vaccine Weekly, June 2nd, 1997
Although it is a potential target for vaccine development, PvMSP1 has not been studied extensively, noted Irene S. Soares and colleagues, Universidade Federal de Sao Paulo, Sao Paulo, Brazil ("Acquired Immune Responses to the N- and C-Terminal Regions of Plasmodium vivax Merozoite Surface Protein 1 in Individuals Exposed to Malaria," Infection and Immunity, May 1997;65:1606-1614).
The researchers evaluated the naturally acquired immune response to PvMSP1 in individuals with recent clinical episodes of malaria...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.